Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Journal of Hepatology|January 7, 2015
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infectionTarek Hassanein, Karen D Sims, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The American Journal of Gastroenterology|August 27, 2019
Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical PracticeJasmohan S Bajaj, Patricia Pringle Bloom, Raymond T Chung, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Journal of Hepatology|January 7, 2015
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infectionTarek Hassanein, Karen D Sims, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The American Journal of Gastroenterology|August 27, 2019
Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical PracticeJasmohan S Bajaj, Patricia Pringle Bloom, Raymond T Chung, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.
Pageof 16